PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis

References

• Taruno A. ATP release channels. Int J Mol Sci. 2018 Mar 11;19(3):808 .
   Google Scholar
• Bhat EA, Sajjad N. Human pannexin 1 channel: insight in structure-function mechanism and its potential physiological roles. Mol Cell Biochem. 2021 Mar;476(3):1529–1540.
   PubMed Web of Science ®Google Scholar
• Vultaggio-Poma V, Sarti AC, Di Virgilio F. Extracellular ATP: a feasible target for cancer therapy. Cells. 2020 Nov 17;9(11):2496.
   PubMed Web of Science ®Google Scholar
• Dahl G. ATP release through pannexon channels. Philos Trans R Soc London, Ser B. 2015 Jul 5;370(1672). DOI:https://doi.org/10.1098/rstb.2014.0191.
   Google Scholar
• Penuela S, Harland L, Simek J, et al. Pannexin channels and their links to human disease. Biochem J. 2014 Aug 1;461(3):371–381.
   PubMedGoogle Scholar
• Faigle M, Seessle J, Zug S, et al. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PloS One. 2008 Jul 30;3(7):e2801.
   PubMed Web of Science ®Google Scholar
• Freeman TJ, Sayedyahossein S, Johnston D, et al. Inhibition of pannexin 1 reduces the tumorigenic properties of human melanoma cells. Cancers (Basel). 2019 Jan 16;11(1):102.
   Web of Science ®Google Scholar
• Sayedyahossein S, Huang K, Li Z, et al. Pannexin 1 binds β-catenin to modulate melanoma cell growth and metabolism. J Biol Chem. 2021 Jan-Jun;296:100478.
   PubMed Web of Science ®Google Scholar
• Penuela S, Gyenis L, Ablack A, et al. Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype. J Biol Chem. 2012 Aug 17;287(34):29184–29193.
   PubMed Web of Science ®Google Scholar
• Sun YY, Zhang TR, Liu FF, et al. Regulatory effect of the pannexin1 channel on invasion and migration of testicular cancer Tcam-2 cells and its possible mechanism. Zhonghua Nan Ke Xue. 2020 Jan;26(1):24–30.
   PubMedGoogle Scholar
• Stewart MK, Plante I, Penuela S, et al. Loss of Panx1 impairs mammary gland development at lactation: implications for breast tumorigenesis. PloS One. 2016;11(4):e0154162.
   PubMed Web of Science ®Google Scholar
• Jalaleddine N, El-Hajjar L, Dakik H, et al. Pannexin1 is associated with enhanced epithelial-to-mesenchymal transition in human patient breast cancer tissues and in breast cancer cell lines. Cancers (Basel). 2019 Dec 7;11(12):1967.
   Web of Science ®Google Scholar
• Furlow PW, Zhang S, Soong TD, et al. Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol. 2015 Jul;17(7):943–952.
   PubMed Web of Science ®Google Scholar
• Laird DW, Penuela S. Pannexin biology and emerging linkages to cancer. Trends Cancer. 2021 Aug 10; DOI:https://doi.org/10.1016/j.trecan.2021.07.002.
   Google Scholar
• Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013 Dec;9(4):491–540.
   PubMed Web of Science ®Google Scholar
• Deshpande M, Notari L, Subramanian P, et al. Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: implications for antitumor activity. Int J Oncol. 2012 Jul;41(1):219–227.
   PubMed Web of Science ®Google Scholar
• Tanimura A, Horiguchi T, Miyoshi K, et al. Differential expression of adenine nucleotide converting enzymes in mitochondrial intermembrane space: a potential role of adenylate kinase isozyme 2 in neutrophil differentiation. PloS One. 2014;9(2):e89916.
   PubMed Web of Science ®Google Scholar
• Kasuya G, Yamaura T, Ma XB, et al. Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel. Nat Commun. 2017 Oct 12;8(1):876.
   PubMedGoogle Scholar
• Woehrle T, Ledderose C, Rink J, et al. Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation. Purinergic Signal. 2019 Jun;15(2):127–137.
   PubMed Web of Science ®Google Scholar
• Mahamed DA, Toussaint LE, Bynoe MS. CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection. Infect Immun. 2015 Feb;83(2):721–729.
   PubMed Web of Science ®Google Scholar
• Luz HL, Reichel M, Unwin RJ, et al. P2X7 receptor stimulation is not required for oxalate crystal-induced kidney injury. Sci Rep. 2019 Dec 27;9(1):20086.
   PubMedGoogle Scholar
• Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel). 2020 Jan 24;12(2):287.
   Web of Science ®Google Scholar
• Lin J, Yu M, Xu X, et al. Identification of biomarkers related to CD8(+) T cell infiltration with gene co-expression network in clear cell renal cell carcinoma. Aging (Albany NY). 2020 Feb 20;12(4):3694–3712.
   PubMedGoogle Scholar
• Guo Y, Wang ZW, Su WH, et al. Prognostic value and immune infiltrates of ABCA8 and FABP4 in stomach adenocarcinoma. Biomed Res Int. 2020;2020:4145164.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: an Open Platform for Exploring Multidimensional Cancer Genomics Data: figure 1. Cancer Discov. 2012 May;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004 Jan-Feb;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021 Mar 15;11(1):6047.
   PubMed Web of Science ®Google Scholar
• Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2016 Jun;13;2:e67.
   Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics. 2019;35(20):4200–4202.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 Jul 2;48(W1):W509–w514.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016 Aug 22;17(1):174.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017 Nov 15;18(1):220.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016 Oct 20;17(1):218.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 May;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017 Nov 13;6. DOI:https://doi.org/10.7554/eLife.26476
   PubMed Web of Science ®Google Scholar
• Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019 May 24;11(1):34.
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017;46(D1):D956–D963.
   Web of Science ®Google Scholar
• van Kollenburg RAA, de Bruin DM, Wijkstra H. Validation of the electronic version of the international index of erectile function (IIEF-5 and IIEF-15): a crossover study. J Med Internet Res. 2019 Jul 2;21(7):e13490.
   PubMed Web of Science ®Google Scholar
• Liu W, Garrett SC, Fedorov EV, et al. Structural basis of CD160: HVEMRecognition. Structure. 2019Aug6; 27(8)1286–1295.e4. London, England: 1993
   PubMed Web of Science ®Google Scholar
• Di Virgilio F, Falzoni S, Giuliani AL, et al. P2 receptors in cancer progression and metastatic spreading. Curr Opin Pharmacol. 2016 Aug;29:17–25.
   PubMed Web of Science ®Google Scholar
• Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2018 Oct;18(10):601–618.
   PubMed Web of Science ®Google Scholar
• Gilbert SM, Oliphant CJ, Hassan S, et al. ATP in the tumour microenvironment drives expression of nfP2X(7), a key mediator of cancer cell survival. Oncogene. 2019 Jan;38(2):194–208.
   PubMed Web of Science ®Google Scholar
• Aswad F, Kawamura H, Dennert G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Iimmunol. 2005 Sep 1;175(5):3075–3083. Baltimore, Md: 1950
   PubMed Web of Science ®Google Scholar
• Adinolfi E, De Marchi E, Orioli E, et al. Role of the P2X7 receptor in tumor-associated inflammation. Curr Opin Pharmacol. 2019 Aug;47:59–64.
   PubMed Web of Science ®Google Scholar
• Lombardi M, Gabrielli M, Adinolfi E, et al. Role of ATP in extracellular vesicle biogenesis and dynamics. Front Pharmacol. 2021;12:654023.
   PubMed Web of Science ®Google Scholar
• Chiu YH, Jin X, Medina CB, et al. A quantized mechanism for activation of pannexin channels. Nat Commun. 2017 Jan;30(8):14324.
   Google Scholar
• Pelegrin P, Surprenant A. The P2X(7) receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal. 2009 Jun;5(2):129–137.
   PubMed Web of Science ®Google Scholar
• Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett. 2004 Aug 13;572(1–3):65–68.
   PubMed Web of Science ®Google Scholar
• Ruan Z, Orozco IJ, Du J, et al. Structures of human pannexin 1 reveal ion pathways and mechanism of gating. Nature. 2020 Aug;584(7822):646–651.
   PubMed Web of Science ®Google Scholar
• Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014 Jan;21(1):79–91.
   PubMed Web of Science ®Google Scholar
• Nouri-Nejad D, O’Donnell BL, Patil CS, et al. Pannexin 1 mutation found in melanoma tumor reduces phosphorylation, glycosylation, and trafficking of the channel-forming protein. Mol Biol Cell. 2021 Mar 1;32(5):376–390.
   PubMed Web of Science ®Google Scholar
• Shi G, Liu C, Yang Y, et al. Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma. J Cancer. 2019;10(23):5681–5688.
   PubMed Web of Science ®Google Scholar
• Ying W, Zheng K, Wu Y, et al. Pannexin 1 mediates gastric cancer cell epithelial–mesenchymal transition via aquaporin 5. Biol Pharm Bull. 2021 Jun 16;44(8):1111–1119.
   PubMed Web of Science ®Google Scholar
• Schulien I, Hockenjos B, van Marck V, et al. Extracellular ATP and purinergic P2Y(2) receptor signaling promote liver tumorigenesis in mice by exacerbating DNA damage. Cancer Res. 2020 Feb 15;80(4):699–708.
   PubMed Web of Science ®Google Scholar
• Takai E, Tsukimoto M, Harada H, et al. Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells. Purinergic Signal. 2014 Sep;10(3):487–497.
   PubMed Web of Science ®Google Scholar
• Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep. 2015 Jul;34(1):103–110.
   PubMed Web of Science ®Google Scholar
• Barclay J, Creswell J, León J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol. 2018 May;71(4):393–399.
   PubMed Web of Science ®Google Scholar
• Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003 Nov;33(11):3117–3126.
   PubMed Web of Science ®Google Scholar
• Sledzińska A, Hemmers S, Mair F, et al. TGF-β signalling is required for CD4⁺ T cell homeostasis but dispensable for regulatory T cell function. PLoS Biol. 2013 Oct;11(10):e1001674.
   PubMed Web of Science ®Google Scholar
• Zhang N, Bevan MJ. Transforming growth factor-β signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. Immunity. 2013 Oct 17;39(4):687–696.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019 Apr 16;50(4):924–940.
   PubMed Web of Science ®Google Scholar
• Castellanos JR, Purvis IJ, Labak CM, et al. B7-H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66–75.
   PubMed Web of Science ®Google Scholar
• Flynn MJ, Hartley JA. The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol. 2017 Oct;179(1):20–35.
   PubMed Web of Science ®Google Scholar
• So T, Ishii N. The TNF-TNFR family of co-signal molecules. Adv Exp Med Biol. 2019;1189:53–84.
   PubMed Web of Science ®Google Scholar
• Eggensperger S, Tampé R. The transporter associated with antigen processing: a key player in adaptive immunity. Biol Chem. 2015 Sep;396(9–10):1059–1072.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020 Sep;20(9):485–503.
   PubMed Web of Science ®Google Scholar
• Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:9624760.
   PubMed Web of Science ®Google Scholar
• Sáez PJ, Vargas P, Shoji KF, et al. ATP promotes the fast migration of dendritic cells through the activity of pannexin 1 channels and P2X(7) receptors. Sci Signal. 2017 Nov21;10(506). DOI:https://doi.org/10.1126/scisignal.aah7107.
   Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298–306.
   PubMed Web of Science ®Google Scholar
• Hoepner S, Loh JM, Riccadonna C, et al. Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. PloS One. 2013;8(5):e63933.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY). 2006 Sep 29;313(5795):1960–1964.
   Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003 Jan 16;348(3):203–213.
   PubMed Web of Science ®Google Scholar
• Burkholder B, Huang RY, Burgess R, et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014 Apr;1845(2):182–201.
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 2;196(5):619–628.
   PubMed Web of Science ®Google Scholar
• Kusuda T, Shigemasa K, Arihiro K, et al. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep. 2005 Jun;13(6):1153–1158.
   PubMed Web of Science ®Google Scholar
• Ubukata H, Motohashi G, Tabuchi T, et al. Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol. 2010 Dec 1;102(7):742–747.
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011 Mar 14;208(3):469–478.
   PubMed Web of Science ®Google Scholar
• Maloney E, Khokhlova T, Pillarisetty VG, et al. Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: an emerging clinical paradigm in the era of personalized oncotherapy. Int Rev Immunol. 2017 Nov 2;36(6):338–351.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016 Aug 6;4(3):28.
   PubMed Web of Science ®Google Scholar
• Ward ST, Li KK, Hepburn E, et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer. 2015 Jan 20;112(2):319–328.
   PubMed Web of Science ®Google Scholar
• Kolb HR, Borcherding N, Zhang W. Understanding and targeting human cancer regulatory T cells to improve therapy. Adv Exp Med Biol. 2021;1278:229–256.
   PubMed Web of Science ®Google Scholar
• Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012 Jan;75(1):95–101.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res off J Am Assoc Cancer Res. 2006 Sep 15;12(18):5423–5434.
   PubMed Web of Science ®Google Scholar
• Jensen HK, Donskov F, Nordsmark M, et al. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2009 Feb 1;15(3):1052–1058.
   PubMed Web of Science ®Google Scholar
• Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019 Jul 15;35(14):i436–i445.
   PubMed Web of Science ®Google Scholar